UroToday - Overactive Bladder (OAB)

Home

Overactive Bladder (OAB)

Overactive Bladder

UroToday's Overactive Bladder section is a repository of the clinical publications, clinical trials and investigative science pertaining to the diagnosis and treatment of overactive bladder. Also available are conference coverage for all timely overactive bladder science, audio podcasts and downloadable slides from UroToday's slide library.

Online Urology & Urologic Oncology Journal
Please read about the UroToday International Journal; We welcome submissions year round and are committed to providing fast-tracked, peer reviewed publication.
Kind regards,
Christian Gratzke, MD
Associate Section Editor Overactive Bladder
UroToday International Journal

Display

results per page

Results 661 - 671 of 671

<< Start < Prev 41 42 43 44 45 Next > End >>

Overactive Bladder Found to be Intimately Associated With Stress Incontinence and Increased Body Mass Index in Middle-Aged Women
Monday, 19 July 2004
BERKELEY, CA (UroToday Inc.) - Female urinary incontinence has been traditionally described and divided by that which occurs in relation to physical exertion (stress urinary incontinence or SUI) and that which is preceded by the presence of the urge to void (urge incontinence).
read more

FDA Approves Indevus's Overactive Bladder Drug
Monday, 31 May 2004
NEW YORK (Reuters) - Indevus Pharmaceuticals Inc. said on Friday that U.S. regulators approved its experimental drug for overactive bladder.
read more

Once-Daily Oxybutynin, Tolterodine Reduce Incontinence in Women With Overactive Bladder
Monday, 23 June 2003
NEW YORK (Reuters Health) - Extended-release oxybutynin and tolterodine are similarly effective for reducing urge urinary incontinence (UUI) and total incontinence episodes in women with overactive bladder, according to a report in the June issue of Mayo Clinic Proceedings.
read more

Data Presentations Support Efficacy and Tolerability of OXYTROL(TM) (Oxybutynin Transdermal System) in Treating Women Suffering From Symptoms of Overactive Bladder
Wednesday, 30 April 2003
NEW ORLEANS, April 30 /PRNewswire/ -- OXYTROL(TM) (oxybutynin transdermal system) is effective, well tolerated, and significantly reduces the number of incontinent episodes associated with overactive bladder (OAB) with a low incidence of anticholinergic side effects, according to three presentations given today during the annual meeting of the American College of Obstetricians and Gynecologists (ACOG).
read more

Nerve Growth Factor and Detrusor Overactivity is There a Physio-Pathogenetic Correlation?
Tuesday, 29 April 2003
TUESDAY, APRIL 29, 2003 (AUA) - Introduction and Objective: Steers & Tuttle in animals and Tanner in humans, showed that chronic bladder outlet obstruction(BOO) causes NGF hyperexpression secondary to the afferent neurons plasticity induced by bladder hypertrophy and that NGF expression increases in idiopathic unstable bladder patients(pts).
read more

Watson Pharmaceuticals' (WPI) OXYTROL Now Available Nationwide; Shipments To More Than 45,000 Pharmacies
Monday, 28 April 2003
CORONA, Calif., April 28 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that OXYTROL(TM) (oxybutynin transdermal system), the first and only transdermal therapy to treat overactive bladder (OAB), with symptoms of urge urinary incontinence, urgency and frequency, is now available nationwide, having shipped to more than 45,000 major pharmacy chain and independent stores.
read more

Increasing Oxybutynin Dose Improves Overactive Bladder Control
Friday, 04 April 2003
WASHINGTON, DC (Reuters Health) - Applying more oxybutynin patches increases the plasma concentration and improves overactive bladder control, according to research presented at the 2003 Annual Meeting of the Society for Clinical Pharmacology and Therapeutics here.
read more

Incontinence Drug Sales Soar
Tuesday, 04 March 2003
TUESDAY, MARCH 04, 2003 (Post Gazette) A multimillion-dollar marketing campaign featuring those "gotta go" TV spots helped quadruple sales of Detrol two years after the drug for overactive bladders was introduced to the U.S. market in 1998. Worldwide, sales increased sixfold.
read more

FDA Approves Watson's Oxytrol TM, First and Only Transdermal Therapy for Overactive Bladder
Wednesday, 26 February 2003
Corona, Calif. - February 26, 2003 - Watson Pharmaceuticals, Inc. (NYSE: WPI), announced today that the U.S. Food and Drug Administration (FDA) has approved OXYTROL tm (oxybutynin transdermal system), the first and only transdermal therapy to treat overactive bladder (OAB), with symptoms of urge urinary incontinence, urgency and frequency.
read more

Overactive Bladder
-
read more

Public Forum on Urinary Incontinence
-
Raising Continence Awareness Second Public Forum - 2008 Friday 24th October Intercontinental Citystars Hotel, Cairo Egypt Continence Worldwide
read more

Focus on Overactive Bladder

Focus on Overactive Bladder condenses a selection of compelling and relevant science - on topic and chosen by the UroToday.com editorial staff.

Podcast - Effective Darifenacin Treatment after Dissatisfaction with Prior Extended-Release Antimuscarinic Therapy

World Continence Week 2009

Patient Guide - Controlling Your Bladder Symptoms

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Promoting Continence Worldwide

- Prepared by Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDM

Urinary Incontinence: Epidemiology and Disease Burden
- Prepared by Alan J. Wein, MD, PhD (hon)

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD

Darifenacin Treatment for Overactive Bladder in Patients Who Expressed Dissatisfaction With Prior Extended-Release Antimuscarinic Therapy
- by Norman Zinner, MD, et al.

Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment
- by Alexander Roosen, MD and Clare J. Fowler, MD

A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive Bladder
- by Giacomo Novara, MD, FEBU

Emerging Drugs for Treatment of Overactive Bladder and Detrusor Overactivity
- by Marcus Drake, MD

Two Types of Urgency
- by Philip M. Hanno, MD, MPH - Editor's Pick

Long-Term Efficacy and Safety of Tolterodine in Children with Neurogenic Detrusor Overactivity
- by Pasquale Casale, MD

Defining Overactive Bladder as Hypersensitivity
- by Philip M. Hanno, MD, MPH

Minimally Invasive Therapy for Neurogenic Detrusor Overactivity: A Review
- by Karl-Erik Andersson, Roger Dmochowski and Alan Wein

A Randomized Controlled Study of Posterior Tibial Nerve Stimulation for Overactive Bladder
- by Paula Palma, MD, PhD. et al.

Efficacy and Tolerability of Add-On Trospium Chloride in Patients with Benign Prostate Syndrome and Overactive Bladder: A Noninterventional Trial Showing Use of Flexible Dosing
- by Ulrich Schwantes, PhD, et al.

The second-line management of idiopathic overactive bladder: What is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?

On the Origins of the Sensory Output from the Bladder: The Concept of Afferent Noise

A Review of Adherence to Drug Therapy in Patients with Overactive Bladder

Sacral Neuromodulation for Treating the Symptoms of Overactive Bladder Syndrome and Non-Obstructive Urinary Retention: More Than 10 Years of Clinical Experience

Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
- by Michael Chancellor, MD, et al.

Obesity is associated with a more severe overactive bladder disease state that is effectively treated with once-daily administration of trospium chloride extended release
- by Michael G. Oefelein, MD, et al.

Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery
- by Michael Chancellor, MD.

The evolution of transdermal therapy for overactive bladder
- by Peter K. Sand, MD

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
- by Michael K. Flynn, MD, et al.

InterStim Therapy: A Contemporary Approach to Overactive Bladder
- by Neeraj Kohli, MD, MBA and Danielle Patterson, MD

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study with Tolterodine and Darifenacin in Healthy Participants > or = 50 years
- by Brian Olshansky, MD, et al.

Randomized Comparison of Tolterodine With Vaginal Estrogen Cream Versus Tolterodine Alone for the Treatment of Postmenopausal Women With Overactive Bladder Syndrome
- by Ling-Hong Tseng, MD, et al.

The role of industry funding in randomized controlled trials of antimuscarinic medications for overactive bladder
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

State of the Art Lecture: Bladder re-innervation: Can new nerves improve the function of the neurogenic bladder?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Is ultrasound bladder wall thickness a better measure than urodynamics for overactive bladder symptoms?
- Session Highlight by Ariana L. Smith, MD from the International Continence Society (ICS) 39th Annual Meeting

Urodynamics/Incontinence/Female Urology: Urodynamic Testing - Identification of Measures of Bladder Sensation in Patients with Overactive Bladder
- Session Highlight by Kathleen Kobashi, MD from the 2009 Annual Meeting of the American Urological Association (AUA)

Session Highlights from the Society for Urodynamics & Female Urology 2009 Winter Meeting
- Exclusive Coverage by UroToday Contributing Medical Editor, William Jaffe, MD

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at The National Institutes of Health (NIH) - UI Symposium
- Session Highlights Reported by Diane K. Newman

Drug Treatment - Lecture Series

- Presented by Karl-Erik Andersson, MD, PhD, and Christopher Chapple, MD, et al. at the Fourth International Consultation on Incontinence (ICI)

Drug Treatment - Committee Meeting Highlights

- Reported by William Jaffe, MD from the Fourth International Consultation on Incontinence (ICI)

Voiding Dysfunction Session Highlights

- From the American Urological Association 2008 Annual Meeting

Urodynamics and Reality

- Presented by Ed McGuire, MD, at the 32nd Winter Urologic Forum

Clinical Proof of Concept Study (BLOSSOM) Shows Novel Beta 3 Adrenoceptor Agonist YM178 is Effective and Well Tolerated in the Treatment of Symptoms of Overactive Bladder
- Presented at the European Association of Urology - 23rd Annual EAU Congress

International Consultation on Incontinence - ICI 2008
- Session Abstracts, Overactive Bladder